Triazolopyridine JAK inhibitor compounds and methods

US8889673B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Bing-Yan Zhu · South San Francisco, US
• Michael Siu · Burlingame, US
• Steven R. Magnuson · South San Francisco, US
• Richard Pastor · South San Francisco, US
• He Haiying · Shanghai, CN
• Xiao Yisong · Shanghai, CN
• Zheng Jifu · Shanghai, CN
• Xu Xing · Chengdu, CN
• Zhao Junping · Yanan, CN
• Wendy Liu · Foster City, US

Key dates

• Filing date: Jun 21, 2012
• Grant date: Nov 18, 2014
• Expiry date: Jun 21, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.